Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment

lillyJanuary 16, 2017

Tag: Rheumatoid Arthritis , Baricitinib

PharmaSources Customer Service